Learn About The SAFE-D Study
In this interview, Dr. Victoria Goss, PhD, Associate Professor of Early Diagnosis and Translational Research, and Head of Early Diagnosis and Translational Group at the Southampton Clinical Trials Unit, discusses the SAFE-D study, the world’s largest study for early detection of pancreatic cancer in patients newly diagnosed with type 2 diabetes. Learn why the study […]
Interview With An Expert – Dr. Talia Golan: Everything You Need To Know About The Evolving Landscape of Pancreatic Cancer Detection
The realm of cancer detection has seen notable advancements, with tests designed to detect a myriad of cancers and those precision-engineered for specific ones. A question then emerges: for a condition as critical as pancreatic cancer, should one lean towards a multi-cancer detection test like Grail’s Galleri or a targeted test like Avantect? Here’s why we advocate the latter.
Targeted Testing For Pancreatic Cancer: Avantect Vs. Multi-Cancer Tests
The realm of cancer detection has seen notable advancements, with tests designed to detect a myriad of cancers and those precision-engineered for specific ones. A question then emerges: for a condition as critical as pancreatic cancer, should one lean towards a multi-cancer detection test like Grail’s Galleri or a targeted test like Avantect? Here’s why we advocate the latter.
How is Pancreatic Cancer Diagnosed
In the ever-evolving landscape of medical diagnostics, the question is not just about “How do you test for pancreatic cancer?” but “What’s the most effective way to test for it?”
Understanding The Limitations of CA19-9 As A Biomarker for Pancreatic Cancer Testing
Among the tools available for pancreatic cancer testing, the biomarker CA19-9 has gained attention for its potential role in monitoring and diagnosis of the disease. In this blog post, we’ll explore what CA19-9 is, how it is used in pancreatic cancer testing, and its limitations as a biomarker.
The Underappreciated Link Between Pancreatic Cancer and Diabetes
Pancreatic cancer is a serious disease with more than 60,000 new cases each year in the U.S. and with expanded impact, that affects a substantial number of people. It’s the third leading cause of cancer-related deaths, and it’s predicted to become the second leading cause by 2030.